Executive Education at LUISS Business School is an experience aimed at inspiring people to develop hard and soft skills, innovative mind-set, entrepreneurship attitude and multi-ethnic interactions. “It is no longer about offering learning to enhance someone’s long term career – says Professor Paolo Boccardelli, the Dean – it is about creating direct impact in support of change. We intend to boost our student professional and personal growth while promoting corporate sustainability and social responsibility”.
LUISS Business School is the School of Business and Management of University LUISS Guido Carli, in Rome (Italy), which leads the development and the growth of individuals and companies. Through the Competence Centres & Labs, which are centres of Business Practice and Research, the School is full embedded in the innovation of the training programmes even thanks to the cooperation with Key Corporate Partners and an International Facultyin order to offer a real change to those who live the experience at LUISS BS.
Its reputation is based on strong values: openness in all the main issues; responsibility, because of its strong commitment with ethically and socially responsible issues; independence, in order to keep safe a very challenging environment.
To view the multimedia release please
http://www.multivu.com/players/English/7588251-luiss-bs-executive-education-italy/
Joshua Melville, son of radical political activist and Attica uprising leader, Sam Melville, works to share personal experience, 25 years of investigative research and documents the government fought to keep hidden. Find out about his endeavors to make his story known at http://igg.me/at/AmericanTimebomb and contact Josh for an interview at MojoMelville@outlook.com Political, memoir
International research led by University College London (UCL) as part of the ‘Cities Changing Diabetes’ partnership programme challenges current scientific understanding of the rapid rise of diabetes in cities. The findings suggest that in cities around the world, social and cultural factors play a far more important role in the spread of the epidemic than previously thought.
More than two thirds of the world’s 400 million people with diabetes live in urban areas.1,2 The year-long study for Cities Changing Diabetes, a unique public-private-academic partnership, sought to better understand what makes people vulnerable to type 2 diabetes in cities in order to inform solutions for one of the most pressing modern-day public health challenges. To explore this complex issue, more than 550 interviews were undertaken with at-risk and diagnosed people in five major cities – Copenhagen, Houston, Mexico City, Shanghai and Tianjin.
“By largely focusing on biomedical risk factors for diabetes, traditional research has not adequately accounted for the impact of social and cultural drivers of disease,” says David Napier, Professor of Medical Anthropology, UCL. “Our pioneering research will enable cities worldwide to help populations adapt to lifestyles that make them less vulnerable to diabetes.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7690951-study-rethink-rise-diabetes-in-cities/
On World Mental Health Day, Janssen has announced the results of a pan-European research project: ‘Talking About Treatment in Schizophrenia: A Patient and Carer Survey’. The survey of 166 adults living with schizophrenia and 468 carers was conducted by the independent market research agency, Fieldwork International (part of Ipsos MORI), and explored awareness, feelings and preferences regarding treatment.
The survey, conducted across 12 countries in Europe (Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Russia, Spain, Sweden, Switzerland and the UK), highlighted key factors affecting the peace of mind for carers, such as the impact of the condition on day‑to-day life, potential relapse/hospitalisation and getting support beyond medication. 94% stated they reminded the person they care for to take their medication and for 49% this happens often.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7947151-janssen-survey-carers-adults-schizophrenia/
Algebra has often been referred to as the “gateway” course with research showing the positive correlation between the early mastering of algebra and college graduation and employment income.
Kumon, the world’s largest after-school math and reading program, understands the importance of advanced study and discovering the true potential of children. As a learning program based on ability rather than age or grade, it is common to see children in Kumon Centers studying math and/or reading material two to three years above their school grade level.
To view the multimedia release go to:
https://www.multivu.com/players/English/7970151-kumon-inaugural-student-conference-disney/
A whopping 80 percent of enterprises are investing today in AI, but one in three business leaders believe their company will need to invest more over the next 36 months to keep pace with competitors. At the same time, enterprises are anticipating significant barriers to adoption and are looking to strategize against those issues by creating a new C-suite position, the Chief AI Officer (CAIO), to streamline and coordinate AI adoption. These results come from a survey of 260 large organizations that operate globally, conducted by leading technology industry market research firm Vanson Bourne on behalf of Teradata (NYSE: TDC), the leading data and analytics company.
“There is an important trend emerging evident in this report — enterprises today see AI as a strategic priority that will help them outpace the competition in their respective industries,” says Atif Kureishy, Vice President, Emerging Practices at Think Big Analytics, a Teradata company. “But to leverage the full potential of this technology and gain maximum ROI, these businesses will need to revamp their core strategies so AI has an embedded role from the data center to the boardroom.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8075951-teradata-state-of-artificial-intelligence-ai-for-enterprises/
Volvo delivers a unique combination of performance and efficiency with the High Performance Drive-E Powertrain Concept - a triple boost 2-liter 4-cylinder petrol engine with no less than 450 hp.
Following the successful introduction of Volvo’s Drive-E Powertrain range in 2013, Volvo’s powertrain team once again demonstrates its technological leadership in emission-reducing turbo technology.
“When we launched the Drive-E powertrain family, our aim was to deliver the most advanced 4-cylinder engines in the industry based on emissions and fuel consumption relative to performance and drivability. We knew that 320 hp in our petrol configuration was just a starting point. The 450 hp High Performance Drive-E Powertrain Concept, demonstrates this ambition and the versatility of the Drive-E Powertrains,” says Dr. Peter Mertens, Senior Vice President for Research and Development at Volvo Car Group.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762550-volvo-reveal-drive-e-450hp-engine/
As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy.
Dr. Ohsumi was honored today during an event at the 2016 BIO International Convention in San Francisco. A video of his acceptance comments can be viewed here.
“Dr. Ohsumi’s curiosity led him to become the first person in the world to determine the molecular mechanism and regulation of autophagy, shedding light on one of the most basic functions of all living cells,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “Dr. Ohsumi’s discoveries hold promise for better understanding, preventing and treating many diseases. It is with great pleasure that we celebrate his contributions, which remind us of the innovative spirit Dr. Paul brought to the lab every day.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7856351-2016-dr-paul-janssen-award-ohsumi/
Team In Training. Light The Night. Man & Woman of the Year. Student Series. Leukemia Cup Regatta. More than 13 million participants in these popular fundraising campaigns last year alone helped The Leukemia & Lymphoma Society (LLS) invest more than $1 billion in research to advance lifesaving treatments and cures for blood cancer patients.
For Blood Cancer Awareness Month this September, LLS is reminding us that despite progress, much work still needs to be done to save more lives. More than 1.2 million people in the U.S. are living with or in remission from a blood cancer. Leukemia causes more deaths than any other cancer among children, adolescents and adults younger than 20 years. Leukemia, lymphoma and myeloma are expected to cause the deaths of an estimated 58,320 people in the U.S. in 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554853-lls-blood-cancer-awareness-month/
Evidence from the Childhood Cancer Survivor Study suggests that changes in childhood cancer treatment have reduced deaths from the late effects of cancer treatment and extended the lives of childhood cancer survivors. St. Jude Children’s Research Hospital investigators led the research, which will be presented today at the plenary session of the 2015 annual meeting of the American Society of Clinical Oncology (ASCO).
The study is one of four being featured at the plenary session press briefing, which highlights research that ASCO deems as having the highest scientific merit and greatest potential to affect patient care.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7532851-st-jude-cancer-research/
The Pharmaceutical Research and Manufacturers of America (PhRMA) today released new advertising as part of its “From Hope to Cures” campaign, highlighting the stories of rare blood and lung cancer survivors.
The newest video in the collection features Matt, who was diagnosed nearly seven years ago with advanced non-small cell lung cancer. When he was diagnosed, he was given a slim chance of living up to five years. However, today Matt continues to lead an active life due to recent advancements in targeted gene therapies and innovations in cancer medicines.
The latest print and digital ads feature Jamie, a vibrant woman diagnosed 15 years ago with chronic myelogenous leukemia (CML). Watching her son grow up was a primary focus for her, and she’s been able to continue to do that and so much more. Thanks to advancements in CML treatments, today she maintains her sense of humor and imparts an infectious joy on those who meet her.
Earlier this year, the first collection of digital and print ads was released featuring Rhys, a five-year-old living with type 1 diabetes and celiac disease. Unveiled alongside the advertising was a video, titled “We’re Fighting Back,” which features both Rhys and Jamie, as well as Jen, a researcher who wakes up every day working to find new treatments and cures for patients.
To view the multimedia release go to:
http://www.multivu.com/players/English/7738431-phrma-from-hope-to-cures/
A new test program by the Insurance Institute for Highway Safety (IIHS) rates the performance of front crash prevention systems to help consumers decide which features to consider and encourage automakers to speed adoption of the technology. The rating system is based on research by the Highway Loss Data Institute (HLDI) indicating that forward collision warning and automatic braking systems are helping drivers avoid front-to-rear crashes.
